copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Home | Global Trial Finder What is a Clinical Trial? A clinical trial, also called a research study, is a scientific evaluation that helps medical professionals learn about an investigational medication or vaccine
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody . . . - Janssen The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion), to determine safety of JNJ-69086420 at the RP2D(s) as a combination therapy in Part 3 (combination therapy) and to determine safety of JNJ-69086420 at the RP2D(s
A Study of Milvexian in Participants After an Acute Ischemic . . . - Janssen Inclusion Criteria: * Ischemic Stroke: a neurological deficit attributable to an acute brain infarction and national institute of health stroke score scale (NIHSS) score less than or equal to (=) 7 and at least 1 of the following: persistent signs or symptoms of the ischemic event
Longkanker in Nederland | Janssen Nederland Diagnose longkanker In Nederland krijgen rond de 14 000 mensen per jaar de diagnose longkanker 1 Het was daarmee in 2020 de derde meest voorkomende vorm van kanker 4 Longkanker is echter niet “één ziekte”, maar is onder te verdelen in meerdere soorten met elk een andere groeisnelheid, verloop en passende behandeling 5 In ongeveer 20% van de gevallen wordt de kanker veroorzaakt door
A Phase 1 2 Study of Bleximenib in Participants With Acute Leukemia The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 (Part 1 [Dose Escalation] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion) The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D
A Study of Amivantamab Alone or in Addition to Other . . . - Janssen The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent metastatic head and neck cancer The study will also confirm the recommended Phase 2 combination dose (RP2CD) for
A Study of Amivantamab Monotherapy and in Addition to . . . - Janssen Colorectal cancer (CRC) is a major global health concern and the third most common cancer worldwide Amivantamab (also known as RYBREVANT or JNJ-61186372) is a fully human immunoglobulin (Ig) G1-based bispecific antibody (Ab) directed against the epidermal growth factor (EGF) and mesenchymal epithelial transition (MET) receptors, with evidence of preclinical activity against non-small cell
Nipocalimab in Moderate to Severe Sjogrens Disease (DAFFODIL) This clinical development program for nipocalimab in SjD includes 2 identical double blind, placebo-controlled studies to evaluate the efficacy, safety, and tolerability of nipocalimab in participants greater than or equal to (>=) 18 years of age with moderate to severe SjD